Sabby Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Sabby Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-23,320	Closed	-$2.02M	–	333
2016 Q1	$1.85M	Buy	23,320 +13,320	+133%	+$1.2M	0.09%	105
2015 Q4	$1.26M	Sell	10,000 -20,000	-67%	-$2.41M	0.07%	164
2015 Q3	$3.12M	Buy	+30,000	New	+$3.85M	0.13%	120
2013 Q4	–	Sell	-336,955	Closed	-$23.5M	–	248
2013 Q3	$25.5M	Buy	336,955 +321,847	+2,130%	+$25.6M	1.66%	16
2013 Q2	$1.21M	Buy	+15,108	New	+$1.11M	0.08%	109

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Sabby Management's VRTX Position: Q2 2016 in Review

Sabby Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2016, closing a stake of 23,320 shares — an estimated $2.02M sold.

Sabby Management first reported a position in VRTX in Q2 2013 and held it in 5 quarters. The position peaked at $25.5M in Q3 2013. 483 funds tracked by Wall St. Rank hold VRTX as of Q2 2016.

Sabby Management reported no remaining Vertex Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Sabby Management sold 23,320 Vertex Pharmaceuticals shares in Q2 2016, an estimated $2.02M.
Sabby Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 5 quarters.
Sabby Management's Vertex Pharmaceuticals position peaked at $25.5M in Q3 2013.
483 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2016.

Based on Sabby Management's 13F filing for Q2 2016, filed 15 Aug 2016.